The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rechallenge with first-generation RET inhibitors in RET-rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.
 
Arianna Marinello
No Relationships to Disclose
 
Julia Rotow
Honoraria - AstraZeneca; Daiichi Sankyo; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bioatla; BMS; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; Genentech; Guardant Health; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Merus; Pfizer; Sanofi/Regeneron; Summit Therapeutics; Takeda
Research Funding - Abbvie (Inst); Altor BioScience (Inst); AstraZeneca (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Enliven Therapeutics (Inst); EpimAb (Inst); ImmunityBio (Inst); Loxo (Inst); ORIC Pharmaceuticals (Inst); RedCloud Biotech (Inst); Regeneron (Inst); Summit Therapeutics (Inst); Synthekine (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Black Diamond Therapeutics; BMS; Johnson & Johnson/Janssen; Merus
 
Meghanne Lomibao
No Relationships to Disclose
 
Rita Leporati
No Relationships to Disclose
 
Jamie Feng
Honoraria - Amgen; AstraZeneca Canada; AstraZeneca Canada; AstraZeneca Canada; AstraZeneca Canada; Merck; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca Canada; Merck
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
Giulio Metro
No Relationships to Disclose
 
Mariana Brandão
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen (Inst); Sanofi (Inst)
Speakers' Bureau - AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
 
Amin Nassar
Stock and Other Ownership Interests - Revolution Medicines; Summit Therapeutics
Honoraria - Capvision; Guidepoint Global; KSMO; Oklahoma University; Putnam Associates; Targeted Oncology; TEMPUS
Travel, Accommodations, Expenses - American Association for Cancer Research; Korean Society of Medical Oncology (KSMO)
 
Fabrizio Citarella
No Relationships to Disclose
 
David Planchard
Honoraria - Medscape; PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Laura Mezquita
Consulting or Advisory Role - AstraZeneca Spain; Janssen; MSD Oncology; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Spain; Janssen Oncology; MSD Oncology; Pfizer; Roche; Takeda
Research Funding - Amgen; AstraZeneca Spain; Bristol-Myers Squibb; Gilead Sciences (Inst); Inivata
Travel, Accommodations, Expenses - AstraZeneca; BMS; Roche; Takeda
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Consulting or Advisory Role - Abbvie (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Enliven Therapeutics (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Takeda (Inst)
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Mihaela Aldea
Consulting or Advisory Role - Viatris
Research Funding - Amgen (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Sandoz